General Information about the vaccine.
Name: BNT162b2 (Generally says Phizer vaccine.)
Type of Vaccine: mRNA
Manufacturer: Pfizer, Inc., and BioNTech
Number of Shots: 2 shots,2nd shot after 21 days.
How Given: Shot in the muscle of the upper arm.
Does NOT Contain: Eggs, preservatives, latex, metals, many more.
H2.Possible Side Effects.
1. In the arm where you got the shot:
(A)Pain
(B)Redness
(C)Swelling
2. Throughout the rest of your body:
(A)Tiredness
(B)Headache
(C)Muscle pain
(D)Chills
(E)Fever
(F)Nausea
These side effects happen within a day or two of getting the vaccine. They are typical signs that your body is building protection and should go away within a few days.
H3.Safety Data Summary.
In clinical trials, reactogenicity symptoms (side effects that happen within seven days of getting vaccinated) were expected but were mostly mild. Some people had side effects that affected their ability to do daily activities.
Side effects (such as fever, chills, tiredness, and headache) throughout the body were more common after the second dose of the vaccine.
CDC will continue to provide updates as we learn more about the safety of the Pfizer-BioNTech vaccine in real-world conditions.
H4.How Well the Vaccine Works.
Based on evidence from clinical trials in people 16 years and older, the Pfizer-BioNTech vaccine was 95% effective at preventing laboratory-confirmed infection with the virus that causes COVID-19 in people who received two doses and had no evidence of being previously infected.
H5.Clinical Trial Demographic Information: 16 Years and Older
Clinical trials for the Pfizer-BioNTech vaccine in people 16 years and older included people from the following racial and ethnic, age, and sex categories:
1. Race
82% White
10% African American
4% Asian
3% other races, multiracial, or race not reported
<1% Native Hawaiian or Other Pacific Islander
<1% American Indian or Alaska Native
2. Ethnicity
73% not Hispanic or Latino
26% Hispanic or Latino
<1% not reported
3. Sex
51% male
49% female
4. Age
58% 16 to 55 years
42% 55 years and older
21% 65 years and older
4% 75 years and older
The most frequent underlying medical conditions among clinical trial participants were obesity (35%), diabetes (8%), and pulmonary disease (8%).
H6.Clinical Trial Demographic Information: 12–15-Year-Olds.
Clinical trials for the Pfizer-BioNTech vaccine in people 12–15 years old included people from the following racial and ethnic, age, and sex categories:
h1.Race
86% White
5% African American
6% Asian
<3% other race, multiracial, or race not reported
<1% Native Hawaiian or Other Pacific Islander
<1% American Indian or Alaska Native
h2.Ethnicity
88% not Hispanic or Latino
12% Hispanic or Latino
<1% not reported
h3.Sex
51% male
49% female
2nd mRNA vaccine.
H1. General Information about the vaccine.
Name: mRNA-1273 (Generally syas Moderna vaccine)
Manufacturer: ModernaTX, Inc.
Type of Vaccine: mRNA
Number of Shots: 2 shots, 2nd shot after 28 days
How Given: Shot in the muscle of the upper arm
Does NOT Contain: Eggs, preservatives, latex, metals
H2. Possible Side Effects.
1. In the arm where you got the shot:
Pain
Redness
Swelling
2. Throughout the rest of your body:
Tiredness
Headache
Muscle pain
Chills
Fever
Nausea
These side effects happen within a day or two of getting the vaccine. They are typical signs that your body is building protection and should go away within a few days.
H3.Safety Data Summary.
In clinical trials, reactogenicity symptoms (side effects that happen within seven days of getting vaccinated) were expected but were mainly mild to moderate.
Side effects throughout the body (such as fever, chills, tiredness, and headache) were more common after the second dose of the vaccine.
H4. How Well the Vaccine Works.
Based on evidence from clinical trials, in people aged 18 years and older, the Moderna vaccine was 94.1% effective at preventing laboratory-confirmed COVID-19 infection in people who received two doses and had no evidence of being previously infected.
The vaccine was also highly effective in clinical trials at preventing COVID-19 among people of diverse ages, sex, race, and ethnic categories and people with underlying medical conditions.
H5. Clinical Trial Demographic Information.
clinical trials for the Moderna vaccine included people from the following racial, ethnic, age, and sex categories:
(h1)Race
79% White
10% African American
5% Asian
<3% other races/ethnicities
<1% American Indian or Alaska Native
<1% Native Hawaiian or Other Pacific Islander
(h2)Ethnicity
79% not Hispanic or Latino
20% Hispanic or Latino
1% unknown
(h3)Sex
53% male
47% female
(h4)Age
75% 18 through 64 years
25% 65 years and older
Twenty-two (22%) of people who participated in the clinical trials had at least one condition that put them at risk of severe illness from COVID-19.
Most people who participated in the trials (82%) were considered an occupational risk of exposure, with 25% of them being healthcare workers.
Source:- cdc.gov
You must be logged in to post a comment.